Organogenesis Holdings, Inc.

As of September 19, 2025, Organogenesis Holdings, Inc. shows a mildly bullish technical trend, supported by bullish MACD and KST indicators, despite a mildly bearish signal from Dow Theory, with a year-to-date return of 43.12%, significantly outperforming the S&P 500.

As of August 6, 2025, Organogenesis Holdings, Inc. has a bullish technical trend, supported by positive MACD indicators and strong performance, outperforming the S&P 500 with a 48.44% year-to-date return.

As of May 8, 2025, Organogenesis Holdings, Inc. is considered overvalued with a high P/E ratio of 28 and a PEG ratio of 0.32, indicating increased risk compared to its peers, despite a year-to-date return of 48.44% that underperforms the S&P 500.

As of May 8, 2025, Organogenesis Holdings, Inc. is considered overvalued due to its high P/E ratio of 28, low returns on capital, and elevated EV to EBITDA ratio, despite a strong stock performance relative to the S&P 500.

As of June 3, 2025, Organogenesis Holdings, Inc. shows a mildly bullish trend based on daily moving averages and monthly MACD, despite mixed signals from weekly indicators and Bollinger Bands.

As of March 2022, the management team of Organogenesis Holdings, Inc. includes President and CEO Gary Gillheeney, Directors Maurice Ades and Glenn Nussdorf, and Independent Directors Alan Ades, Albert Erani, and Arthur Leibowitz. They oversee the company's strategic direction and operations.

Organogenesis Holdings, Inc. is a regenerative medicine company specializing in advanced wound care, surgical, and sports medicine products. As of March 2025, it reported net sales of $87 million and a net loss of $19 million, with a market cap of $399.33 million.

As of Jun 18, Organogenesis Holdings, Inc. has a market capitalization of 399.33 million and reported net sales of 458.76 million with a net profit of -15.88 million over the latest four quarters.